{"product_id":"biolegend-504106","title":"Biolegend, 504106, APC anti-mouse IL-4 Antibody, 100μg","description":"\u003cp\u003eIL-4 is a pleiotropic cytokine produced by activated T cells, mast cells, and basophils. IL-4 is a potent lymphoid cell growth factor which stimulates the growth and activation of certain B cells and T cells. IL-4 is important for regulation of T helper subset development.\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: Partially purified native mouse IL-4\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.\u003cbr\u003e\nConcentration: 0.2 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: ICFC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nExcitation Laser: Red Laser (633 nm)\u003cbr\u003e\nApplication Notes: ELISA1,2,10,13 or ELISPOT5 Capture: The purified 11B11 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD6-24G2 antibody (Cat. No. 504202) as the detecting antibody and recombinant mouse IL-4 (Cat. No. 575609) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture.Neutralization1-2,9,12: The 11B11 antibody can neutralize the bioactivity of natural or recombinant IL-4. The LEAF™ purified antibody (Endotoxin \u0026lt;0.1 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IL-4 bioactivity in vivo and in vitro (Cat. No. 504108).Additional reported applications (for the relevant formats) include: immunoprecipitation16, immunohistochemical staining of formalin-fixed paraffin-embedded tissue sections8 and paraformaldehyde-fixed, saponin-treated frozen tissue sections6,7, and immunocytochemistry4.Note: For testing mouse IL-4 in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 431101 to 431106) are specially developed and recommended.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Shirai A, et al. 1994. Cytokine 6:329. (ELISA, Neut) Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20. (ELISA, Neut) Assenmacher M, et al. 1994. Eur. J. Immunol. 24:1097. Openshaw P, et al. 1995. J. Exp. Med. 182:1357. (ICC) Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19. (ELISA Capture) Litton M, et al. 1994. J. Immunol. Methods 175:47. (IHC) Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Hara M, et al. 2001. J. Immunol. 166:3789. (Neut) Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA) Lawson BR, et al. 2007. J. Immunol. 178:5366. Wang W, et al. 2007. J. Immunol. 178:4885. (Neut) Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed Ohnmacht C, et al. 2008. Blood 113:2816. PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Zavorotinskaya T, et al. 2003. Mol. Ther. 7:155. (IP)\u003cbr\u003e\nProduct Citations: Elong Ngono A, et al. 2020. Cell Reports. 1.330555556. PubMed Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed Deák P, et al. 2022. Cell Rep. 41:111563. PubMed Giampaolo S, et al. 2023. iScience. 26:106234. PubMed McCauley KE, et al. 2022. Cell Rep Med. 3:100713. PubMed Mansouri S, et al. 2022. J Immunol. 209:2114. PubMed Weng S, et al. 2022. Front Immunol. 13:1025931. PubMed Sun Y, et al. 2023. Cell Mol Life Sci. 80:63. PubMed Nanishi E, et al. 2023. NPJ Vaccines. 8:18. PubMed Zhao X, et al. 2022. Cell Mol Immunol. 19:540. PubMed Kim CJ, et al. 2018. Immunity. 49:1034. PubMed Mei S, et al. 2022. Front Immunol. 13:911164. PubMed Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed Cai B, et al. 2021. Mol Cancer. 20:165. PubMed Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed Hegde S, et al. 2020. Cancer Cell. 37(3):289-307. PubMed Pu Y, et al. 2022. Transl Psychiatry. 12:223. PubMed Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed Chang Q, et al. 2020. Scand J Immunol. 92:e12877. PubMed Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed Guo J, et al. 2022. Nat Biomed Eng. 6:19. PubMed Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed Yan J, et al. 2020. Cell Rep. 107820:31. PubMed Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed Jin R, et al. 2008. J Immunol. 180:2256. PubMed Li X, et al. 2016. MBio. 7: 02232-15. PubMed Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed Wen J, et al. 2020. Cell Rep. 31:107566. PubMed Kiuchi M, et al. 2021. J Exp Med. 218:. PubMed Fukuishi N, et al. 2014. J Immunol. 193:1886. PubMed Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed Wawrzyniak M, et al. 2021. Pharmacol Res Perspect. 9:e00837. PubMed Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed Liu YW, et al. 2022. JCI Insight. 7:. PubMed DiMarco AV, et al. 2022. Cancer Immunol Res. 10:70. PubMed Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed\u003cbr\u003e\nRRID: AB_315319 (BioLegend Cat. No. 504105) AB_315320 (BioLegend Cat. No. 504106)\u003cbr\u003e\nStructure: Cytokine; 15-19 kD (Mammalian)\u003cbr\u003e\nBioactivity: Differentiation of naïve CD4+ T cells to the TH2 type, proliferation\/differentiation of activated B cells, expression of class II MHC antigens, and of low affinity IgE receptors in resting B cells\u003cbr\u003e\nCell Sources: Mast cells, T cells, bone marrow stromal cells\u003cbr\u003e\nCell Targets: B cells, T cells, monocytes, endothelial cells, fibroblasts\u003cbr\u003e\nReceptors: Heterodimer IL-4Rα (CD124); γ-subunit (CD132) in common with IL-2R, IL-7R, IL-13R, IL-15R\u003cbr\u003e\nCell Type: Tregs\u003cbr\u003e\nBiology Area: Immunology\u003cbr\u003e\nMolecular Family: Cytokines\/Chemokines\u003cbr\u003e\nAntigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego. 2. Boulay J, et al. 1992. Curr. Opin. Immunol. 4:294. 3. Dullens H, et al. 1991. In vivo 5:567. 4. Paul W. 1991. Blood 77:1859.\u003cbr\u003e\nRegulation: Upregulated by IL-2, platelet activating factor; downregulated by TGF-β\u003cbr\u003e\nGene ID: 16189\u003cbr\u003e\nUniProt: View information about IL-4 on UniProt.org\u003cbr\u003e\nClone: 11B11\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Interleukin-4, Ia inducing factor (IaIF), B cell stimulating factor-1 (BSF-1), Hodgkin's cell growth factor (HCGF), Mast cell growth factor-2 (MCGF-2), Macrophage fusion factor (MFF), T cell growth factor-2 (TCGF-2)\u003cbr\u003e\nIsotype: Rat IgG1, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46860790235305,"sku":"504106","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/biolegend-504106","provider":"Iright","version":"1.0","type":"link"}